Resource impact statement
No significant resource impact is anticipated
NICE has recommended budesonide as an option for inducing remission of eosinophilic oesophagitis in adults.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3m).
This is because the overall incremental cost of treatment is low and eosinophilic eosophagitis is a rare condition affecting around 13,000 people in England.
This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: